← BridgeBio Pharma, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $92.0m | $436.1m | $363.8m | $356.1m | $393.8m | $376.7m | $375.9m | $681.1m | $570.1m | $13k | |
| Prepaid Expense and Other Assets, Current | — | $9.1m | $22.6m | $35.7m | $32.4m | $21.9m | $24.3m | $34.7m | $44.1m | — | |
| Accounts receivable, net | — | — | — | — | — | — | $1.8m | $4.7m | $139.4m | — | |
| Prepaid expenses and other current assets | — | $9.1m | $22.6m | $35.7m | $32.4m | $21.9m | $24.3m | $34.7m | $44.1m | — | |
| Prepaids and other current assets | — | — | — | — | $655k | $644k | $49k | $248k | $205k | — | |
| Inventory, Net | — | — | — | — | — | — | — | $0 | $26.8m | — | |
| Assets, Current | — | $445.2m | $568.6m | $642.8m | $888.9m | $548.9m | $477.6m | $720.7m | $797.7m | — | |
| Total current assets | — | $445.2m | $568.6m | $642.8m | $888.9m | $548.9m | $477.6m | $720.7m | $797.7m | $204k | |
| Property, Plant and Equipment, Net | — | $1.6m | $5.6m | $20.3m | $30.1m | $14.6m | $11.8m | $7.0m | $5.4m | — | |
| Intangible Assets, Net (Excluding Goodwill) | — | — | — | $0 | $44.9m | $28.7m | $26.3m | $23.9m | $28.1m | — | |
| Operating Lease, Right-of-Use Asset | — | — | $10.0m | $16.5m | $15.9m | $10.7m | $8.0m | $5.8m | $8.1m | — | |
| Other Assets, Noncurrent | — | $1.1m | $26.3m | $23.9m | $33.0m | $20.2m | $22.6m | $18.2m | $16.7m | — | |
| Operating lease right-of-use assets | — | — | — | $16.5m | $15.9m | $10.7m | $8.0m | $5.8m | $8.1m | — | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | — | — | — | — | $4.7m | $139.4m | — | |
| Marketable securities | — | — | — | — | $393.7m | $51.6m | $0 | $0 | $17.4m | — | |
| Equity method investments | — | — | — | — | — | — | — | $143.7m | $80.0m | — | |
| Operating lease liabilities, current portion | — | — | — | $3.8m | $4.9m | $3.7m | $4.1m | $4.5m | $6.2m | — | |
| Other current liabilities | — | — | — | — | — | — | — | $33.1m | $120.2m | — | |
| 2031 Notes, 2029 Notes, 2027 Notes, and Term Loan, net | — | $54.5m | $91.8m | $92.4m | $430.8m | $431.0m | $446.4m | $437.3m | $1.9b | — | |
| Deferred royalty obligations, net | — | — | — | — | — | — | $0 | $479.1m | $855.0m | — | |
| Operating lease liabilities, net of current portion | — | — | — | $14.7m | $17.4m | $12.3m | $9.0m | $4.7m | $3.8m | — | |
| Financial guarantee liability (Note 16(c)) | — | — | — | — | $182k | $219k | $667k | $550k | $382k | $413k | |
| Convertible debentures (Note 5) | — | — | — | — | $500k | $238k | $0 | $245k | $821k | $285k | |
| Loans payable (Note 6) | — | — | — | — | $0 | $40k | $80k | $0 | $50k | $74k | |
| Promissory notes (Note 7) | — | — | — | — | — | — | — | — | $0 | $425k | |
| Warrant liabilities (Notes 9(a) and 9(b)) | — | — | — | — | — | — | — | — | $313k | $115k | |
| Common shares issuable (Notes 8(d) and 8(j)) | — | — | — | — | — | — | $74k | $0 | $43k | $241k | |
| Deficit attributable to shareholders | — | — | — | — | — | — | ($10.7m) | ($10.8m) | ($10.7m) | ($9.8m) | |
| Warrant liabilities (Notes 10(a) and 10(b)) | — | — | — | — | $132k | — | $21k | $275k | — | — | |
| Reserves (Notes 10(c), 11 and 12) | — | — | — | — | $22.6m | $23.7m | $24.6m | $25.6m | — | — | |
| Total BridgeBio stockholders’ deficit | $85.9m | $314.9m | $408.5m | $57.9m | ($870.4m) | ($1.3b) | ($1.4b) | ($1.5b) | ($2.1b) | — | |
| Total stockholders’ deficit | $88.3m | $377.2m | $473.7m | $106.3m | ($867.0m) | ($1.2b) | ($1.3b) | ($1.5b) | ($2.1b) | — | |
| Total Equity Including Noncontrolling Interest | — | — | — | — | — | — | — | $25.6m | $27.7m | $27.9m | |
| Total deficit | — | — | — | — | ($4.6m) | ($3.9m) | ($7.5m) | ($7.7m) | ($7.4m) | ($6.5m) | |
| Total Cash | — | — | — | — | $155k | $174k | $8k | $37k | $8k | — | |
| Assets | — | $464.9m | $631.7m | $703.6m | $1.0b | $623.0m | $546.4m | $919.3m | $936.0m | $220k | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | $8.0m | $3.8m | $4.9m | $3.7m | $4.1m | $4.5m | $6.2m | — | |
| Accounts Payable, Current | — | $13.5m | $8.9m | $8.9m | $11.9m | $11.6m | $10.7m | $9.6m | $36.2m | — | |
| Operating Lease, Liability, Noncurrent | — | — | — | $14.7m | $17.4m | $12.3m | $9.0m | $4.7m | $3.8m | — | |
| Deferred Revenue, Current | — | — | — | — | $0 | $8.2m | $6.1m | $14.6m | $7.2m | — | |
| Long-term Debt, Current Maturities | — | — | — | $1.5m | — | — | — | — | — | — | |
| Long-term Debt, Excluding Current Maturities | — | $54.5m | $91.8m | $92.4m | $430.8m | $431.0m | $446.4m | $437.3m | — | — | |
| Accrued compensation and benefits | — | $4.0m | $13.3m | $29.7m | $37.0m | $31.3m | $57.4m | $58.3m | $76.7m | — | |
| Accrued research and development liabilities | — | $8.9m | $20.9m | $27.3m | $44.1m | $39.8m | $29.8m | $34.3m | $41.4m | — | |
| Accounts payable and accrued liabilities | — | — | — | — | $4.5m | $3.3m | $5.4m | $5.0m | $4.5m | $4.0m | |
| Liabilities, Current | — | $32.6m | $60.4m | $95.6m | $135.1m | $121.4m | $143.8m | $154.4m | $288.0m | — | |
| Total current liabilities | — | $32.6m | $60.4m | $95.6m | $135.1m | $121.4m | $143.8m | $154.4m | $288.0m | $1.4m | |
| Other Liabilities, Noncurrent | — | $495k | $3.5m | $9.5m | $22.1m | $26.6m | $9.4m | $286k | $244k | — | |
| Other long-term liabilities | — | $495k | $3.5m | $9.5m | $22.1m | $26.6m | $9.4m | $286k | $244k | — | |
| Deferred Tax Liabilities, Net | — | — | — | $1.1m | — | — | — | — | — | — | |
| Liabilities | — | $87.6m | $155.7m | $595.7m | $1.9b | $1.9b | $1.9b | $2.4b | $3.0b | $6.7m | |
| Total liabilities and deficit | — | — | — | — | $1.4m | $1.2m | $75k | $325k | $225k | $220k | |
| Redeemable Noncontrolling Interest, Equity, Carrying Amount | — | — | — | — | — | — | — | $25.6m | ($570k) | $27.9m | |
| Redeemable convertible noncontrolling interests | $833k | $122k | $2.2m | $1.6m | $1.4m | ($1.6m) | $478k | $142k | ($570k) | — | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | — | — | — | — | — | $0 | $0 | — | |
| Common Stock, Value, Issued | $51k | $92k | $124k | $125k | $154k | $157k | $181k | $196k | $202k | — | |
| Additional Paid in Capital | $134.5m | $494.2m | $848.1m | $1.0b | $841.5m | $938.7m | $1.5b | $1.9b | $2.1b | — | |
| Retained Earnings (Accumulated Deficit) | ($48.7m) | ($179.4m) | ($440.0m) | ($888.8m) | ($1.4b) | ($1.9b) | ($2.6b) | ($3.1b) | ($3.8b) | ($120.1m) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | — | — | $254k | $192k | ($132k) | ($328k) | $31k | $8k | $12k | $201k | |
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — | — | — | — | — | — | 0 | 0 | — | |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of December 31, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of December 31, 2024 | 51k | 92k | 124k | 125k | 154k | 157k | 181k | 196k | 202k | — | |
| Treasury stock, at cost; 7,597,172 shares as of December 31, 2025; 6,191,761 shares as of December 31, 2024 | — | — | — | — | — | — | — | ($275.0m) | ($323.3m) | — | |
| Stockholders' Equity Attributable to Parent | — | $314.9m | $408.5m | $57.9m | ($870.4m) | ($1.3b) | ($1.4b) | ($1.5b) | ($2.1b) | — | |
| Stockholders' Equity Attributable to Noncontrolling Interest | — | $62.4m | $65.3m | $48.4m | $3.4m | $11.3m | $11.2m | $10.2m | $10.6m | $27.9m | |
| Noncontrolling interests | $2.5m | $62.4m | $65.3m | $48.4m | $3.4m | $11.3m | $11.2m | $10.2m | $10.6m | — | |
| Noncontrolling Interest | — | — | — | — | — | — | $3.2m | $3.1m | $3.3m | $3.3m | |
| Total Stockholders' Equity | — | — | — | — | $63.7m | $75.4m | $76.6m | $78.5m | $80.0m | $82.0m | |
| Liabilities and Equity | — | $464.9m | $631.7m | $703.6m | $1.0b | $623.0m | $546.4m | $919.3m | $936.0m | — | |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | — | $464.9m | $631.7m | $703.6m | $1.0b | $623.0m | $546.4m | $919.3m | $936.0m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.